Omnicell (OMCL) Free Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Omnicell (OMCL) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | 28.87% |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 69.33% |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | 120.89% |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 14.12% |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 13.29% |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 142.84% |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | -0.16% |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | -11.68% |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | -20.60% |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | 91.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91.69% |
| Mar 31, 2026 | 185.15% |
| Dec 31, 2025 | -52.05% |
| Sep 30, 2025 | 33.33% |
| Jun 30, 2025 | -36.98% |
| Mar 31, 2025 | -64.02% |
| Dec 31, 2024 | 60.95% |
| Sep 30, 2024 | -70.06% |
| Jun 30, 2024 | -19.79% |
| Mar 31, 2024 | 1,459.38% |
| Dec 31, 2023 | -57.15% |
| Sep 30, 2023 | 451.23% |
| Jun 30, 2023 | 419.77% |
| Mar 31, 2023 | 109.57% |
| Dec 31, 2022 | 41.03% |
| Sep 30, 2022 | -76.74% |
| Jun 30, 2022 | -129.12% |
| Mar 31, 2022 | -152.53% |
| Dec 31, 2021 | -31.49% |
| Sep 30, 2021 | 10.82% |